Press Release
Jun 07, 2019
What: The International Association for the Study of Lung Cancer (IASLC) will host the IASLC 2019 Mesothelioma Meeting in New York City, July 10-12.
When: July 10-12, 2019
Where: Westin New York at Times Square
Background: The Food and Drug Administration approved the first therapy to treat mesothelioma in 15 years when it approved NOVO TTF-100L on May 24. Despite tighter regulation and less reliance of building products that contain asbestos, the number of deaths from mesothelioma are still high. Amidst this background, researchers, clinicians, public health advocates and government officials gather in New York to share new research and ideas on how to decrease the impact of mesothelioma.
Meeting Highlights: Scheduled sessions include the following topics:
- Immune Checkpoint Inhibitors as Single Agents
- PD-L1 Testing and Tumor Mutation Burden Testing Should/Should Not be Done Before Selecting Immunotherapy in Malignant Pleural Mesothelioma
- Anti-Metabolites and Chemotherapy
- Mesothelin-Targeting Agents
- Genomic Profiling Should/Should Not be Standard of Care in Malignant Pleural Mesothelioma
- Immune Checkpoint Inhibitors + Chemo or Other Immune Combination Co Stimulatory and Co-Inhibitor Molecules
- A panel on Mesothelioma Research, with representatives from the National Cancer Institute, Food and Drug Administration and the Cancer Therapy Education Program
- Vaccines and Intrapleural Gene Therapy
Interview Opportunities: Members of the media will have the opportunity to discuss advancements in mesothelioma with leading researchers and clinicians in the field.
Media Registration: To register for the conference as a credentialed member of the media, email Chris Martin at cmartin@davidjamesgroup.com.
For More Information: Visit https://www.iaslc.org/Conferences-Events/Event-Details/iaslc-2019-mesothelioma-meeting for more information, including a full schedule of conference events.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.